A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

BACKGROUND: Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the sponsor entering a ‘managed entry scheme’ to assess the 2-year overall survival rate in metastatic melanoma patients who received ipilimumab in the first year o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hansoo, Comey, Samantha, Hausler, Karl, Cook, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810048/
https://www.ncbi.nlm.nih.gov/pubmed/29456865
http://dx.doi.org/10.1186/s40545-018-0131-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810048/
https://www.ncbi.nlm.nih.gov/pubmed/29456865
http://dx.doi.org/10.1186/s40545-018-0131-4

Ejemplares similares